GLP-1 Market
LLY $1164.89 ▲ +1.0% NVO $39.80 ▼ -8.0% PFE $27.74 ▲ +0.3% VKTX $30.11 ▲ +3.9% KLRA $11.99 ▼ -6.5% GPCR $36.81 ▲ +5.2% RHHBY $55.30 ▲ +2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Olatorepatide

Company
Regeneron Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for Olatorepatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07057674

    A Study of HS-20094 in Overweight or Obese Participants

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 144 participants Est. completion 2026-05-29 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Recruiting NCT NCT07685808

    Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

    Not yet reported Regeneron Pharmaceuticals 360 participants Est. completion 2028-01-21 5 sites Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Status unknown NCT NCT05116410

    A Study of HS-20094 in Healthy Participants

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 68 participants Est. completion 2022-12-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06118008

    A Study of HS-20094 in T2DM Participants

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 54 participants Est. completion 2024-01-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06118021

    A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 200 participants Est. completion 2024-08-13 2 sites Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06839664

    A Study of HS-20094 in Chinese Adults With Overweight or Obesity

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 604 participants Est. completion 2026-01-30 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT06901648

    A Study of HS-20094 in Patients With T2DM

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 275 participants Est. completion 2025-04-09 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07156500

    A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 204 participants Est. completion 2027-05-30 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07156539

    A Phase 3 Study of HS-20094 in Patients With T2DM

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 546 participants Est. completion 2027-05-30 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07431086

    Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

    Not yet reported Regeneron Pharmaceuticals 120 participants Est. completion 2026-12-18 3 sites Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07830329

    Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

    Not yet reported Regeneron Pharmaceuticals 300 participants Est. completion 2028-12-22 Stand-alone
    Other conditions: Hidradenitis Suppurativa
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Olatorepatide, HS-20094

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.